CC
MRNA icon

Centiva Capital’s Moderna MRNA Stock Holding History

Centiva Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$552K – 1572
2025
Q2 		$552K Buy
+20,000
New +$527K 0.01% 913
2025
Q1 		– Sell
-7,200
Closed -$299K – 1926
2024
Q4 		$299K Buy
7,200
+3,300
+85% +$158K 0.01% 1142
2024
Q3 		$261K Sell
3,900
-3,100
-44% -$285K 0.01% 1666
2024
Q2 		$831K Buy
+7,000
New +$886K 0.01% 866
2024
Q1 		– Sell
-3,000
Closed -$298K – 2060
2023
Q4 		$298K Sell
3,000
-8,600
-74% -$723K 0.01% 1204
2023
Q3 		$1.2M Sell
11,600
-9,000
-44% -$1M 0.03% 551
2023
Q2 		$2.5M Sell
20,600
-29,100
-59% -$3.88M 0.05% 322
2023
Q1 		$7.63M Sell
49,700
-53,900
-52% -$8.89M 0.19% 106
2022
Q4 		$18.6M Buy
103,600
+29,500
+40% +$4.82M 0.53% 23
2022
Q3 		$8.76M Sell
74,100
-41,500
-36% -$6.3M 0.16% 76
2022
Q2 		$16.5M Buy
115,600
+70,000
+154% +$10M 0.39% 27
2022
Q1 		$7.85M Sell
45,600
-48,700
-52% -$8.2M 0.15% 90
2021
Q4 		$23.9M Buy
94,300
+88,360
+1,488% +$25.8M 0.49% 35
2021
Q3 		$2.28M Sell
5,940
-56,960
-91% -$21M 0.14% 147
2021
Q2 		$14.8M Buy
62,900
+30,600
+95% +$5.47M 0.35% 47
2021
Q1 		$4.23M Buy
+32,300
New +$4.68M 0.16% 97

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Centiva Capital's MRNA Position: Q2 2026 in Review

Centiva Capital sold out of Moderna (MRNA) in Q2 2026, closing a stake of 2,733 shares — an estimated $139K sold.

Centiva Capital first reported a position in MRNA in Q2 2020 and held it in 15 quarters. The position peaked at $5.92M in Q1 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Centiva Capital reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 2,733 Moderna shares in Q2 2026, an estimated $139K.
  • Centiva Capital first reported a position in Moderna in Q2 2020 and held it in 15 quarters.
  • Centiva Capital's Moderna position peaked at $5.92M in Q1 2022.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.